Discover insights from Corcept Therapeutics' Q1 2025 earnings call: revenue growth, relacorilant's FDA review, and its strategic outlook ...

Corcept attributed the revenue shortfall to supply chain issues at its specialty pharmacy vendor early in the quarter, which impacted its ability to fulfill a surge in demand. The company noted that ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

For the past 7 years, Bayer has shelled out billions of dollars in lawsuits brought by people claiming they developed cancer after exposure to its glyphosate-containing weed killers, including its ...

A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a ...

A panelist discusses how multiple molecular biomarkers beyond BRCA and homologous recombination deficiency (HRD) testing are ...

INX-315 is an oral, investigational selective cyclin-dependent kinase 2 (CDK2) inhibitor. The designation was based on preclinical data as well as interim data from the ongoing phase 1/2 INX-315-01 ...